Archives for February 2019

Panel Overwhelmingly Recommends FDA Approve Esketamine for Resistant Depression

On February 12th, an FDA advisory panel recommended overwhelmingly that the agency approve a drug called esketamine for the rapid relief of depression in patients who have not been helped by existing therapies. If approved, the drug will also be used to reduce suicidal thinking in patients in crisis, where it has also shown effectiveness in tests.

Like the closely related experimental drug ketamine, which has been used for years as an anesthetic, esketamine has been shown in multiple clinical trials to dramatically reduce the symptoms of even intractable depression in many patients, often within minutes or hours of its administration. Its effects typically last 1 to 2 weeks, but can be continued in “maintenance” dosing following initial treatment, clinical trials have suggested.

Read entire article HERE.